Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia
Document Type
Article
Abstract
Abstract Introduction Down syndrome (DS) is associated with amyloid b (Ab) deposition. Methods We characterized imaging measurements of regional fibrillar Ab burden, cerebral metabolic rate for glucose (rCMRgl), gray matter volumes (rGMVs), and age associations in 5 DS with dementia (DS/AD1), 12 DS without dementia (DS/AD2), and 9 normal controls (NCs). Results There were significant group differences in mean standard uptake value ratios (SUVRs) for florbetapir with DS/AD1 having the highest, followed by DS/AD2, followed by NC. For [18F]-fluorodeoxyglucose positron emission tomography, posterior cingulate rCMRgl in DS/AD1 was significantly reduced compared with DS/AD2 and NC. For volumetric magnetic resonance imaging (vMRI), hippocampal volumes were significantly reduced for the DS/AD1 compared with DS/AD2 and NC. Age-related SUVR increases and rCMRgl reductions were greater in DS participants than in NCs. Discussion DS is associated with fibrillar Ab, rCMRgl, and rGMV alterations in the dementia stage and before the presence of clinical decline. This study provides a foundation for the studies needed to inform treatment and prevention in DS.
Publication Date
8-1-2015
Publication Title
Alzheimer's and Dementia
ISSN
15525260
E-ISSN
15525279
Volume
11
Issue
8
First Page
994
Last Page
1004
PubMed ID
25849033
Digital Object Identifier (DOI)
10.1016/j.jalz.2015.01.006
Recommended Citation
Sabbagh, Marwan N.; Chen, Kewei; Rogers, Joseph; Fleisher, Adam S.; Liebsack, Carolyn; Bandy, Dan; Belden, Christine; Protas, Hillary; Thiyyagura, Pradeep; Liu, Xiaofen; Roontiva, Auttawut; Luo, Ji; Jacobson, Sandra; Malek-Ahmadi, Michael; Powell, Jessica; and Reiman, Eric M., "Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia" (2015). Neurology. 886.
https://scholar.barrowneuro.org/neurology/886